Skip to main content

Dake Benjamin T's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Nov 14, 2022

Accession no.
0001415889-22-011356
Filed
Nov 14, 2022
Trade date
Nov 9-11, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 8 non-derivative transactions and 3 derivative transactions. Open-market sales total $415.2K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dake Benjamin TCIK 0001869248Officer (SEE REMARKS)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 9, 2022Common StockMOption exerciseAcquired+14,000$2.14+$29,96014,000Direct
Nov 9, 2022Common StockSSaleDisposed−14,000$17.91F2−$250,7400Direct
Nov 10, 2022Common StockMOption exerciseAcquired+1,800$2.14+$3,8521,800Direct
Nov 10, 2022Common StockSSaleDisposed−1,800$20.10F3−$36,1800Direct
Nov 11, 2022Common StockMOption exerciseAcquired+6,198$2.14+$13,263.726,198Direct
Nov 11, 2022Common StockSSaleDisposed−4,452$20.39F4−$90,776.281,746Direct
Nov 11, 2022Common StockSSaleDisposed−1,625$21.41F5−$34,791.25121Direct
Nov 11, 2022Common StockSSaleDisposed−121$22.20F6−$2,686.20Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 9, 2022Common StockMOption exerciseDisposed−14,000$0.00$0262,598Direct
Nov 10, 2022Common StockMOption exerciseDisposed−1,800$0.00$0260,798Direct
Nov 11, 2022Common StockMOption exerciseDisposed−6,198$0.00$0254,600Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.49 to $18.26, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.02 to $20.406, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F4

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.00 to $20.965, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.02 to $21.96, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

F6

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.16 to $22.205, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

Officer Title: President, Chief Operating Officer and Secretary

Read the full filing on SEC EDGAR (opens in a new tab)